Antipsychotic Medications and Weight Gain: A Dose-Dependent Analysis and Clinical Implications

This podcast episode, hosted by psychiatrist Dr. Tracey Marks, delves into the significant side effect of weight gain associated with antipsychotic medications, which are used not only for psychotic conditions like schizophrenia but also for bipolar disorder and depression. Dr. Marks highlights a new research study published in the Journal of Clinical Psychiatry that analyzed 52 randomized controlled trials involving 22,000 people, providing crucial insights into the dose-dependent nature of weight gain and metabolic changes caused by these drugs. The study clarified that for most antipsychotics, higher doses lead to more weight gain, moving beyond a simple binary model.

The episode distinguishes between two patterns of weight gain: the "plateau effect," where weight gain stabilizes after a certain point even with increased dosage, and the more concerning "creep effect," where weight continues to increase with higher doses and over longer periods of medication use. Dr. Marks then ranks 10 common antipsychotics from most to least weight-gaining, detailing specific weight increases over six weeks and noting whether they exhibit the creep or plateau effect. Olanzapine (Zyprexa) is identified as the worst offender, causing an average of eight pounds in six weeks with a creep effect, while Lurasidone (Latuda) causes the least, at one pound over six weeks.

Practical insights and recommendations for both patients and clinicians are emphasized. Given the dose-dependent nature of weight gain and metabolic changes (increases in glucose, triglycerides, and cholesterol), Dr. Marks advises aiming for the least effective dose possible to minimize negative effects. While higher doses might be necessary during acute phases of illness, she suggests that doctors consider lowering maintenance doses once symptoms improve, especially for medications with the creep effect. The importance of regular medical checks and blood work to monitor metabolic functioning is also stressed.

Broader implications include the ongoing challenge of balancing medication efficacy with quality of life and long-term health outcomes for psychiatric patients. The episode underscores the need for personalized medicine, acknowledging that some patients may only respond to specific medications despite their side effects. It also highlights the critical role of informed decision-making and ongoing dialogue between patients and their healthcare providers to manage the complex interplay between mental health treatment and metabolic health.

"All of the medications they studied had a dose-dependent relationship with weight gain, meaning higher doses caused more weight gain."

"However, some medications plateaued so that you gained weight up until a certain point, then it leveled off even if your dose continued to increase."

"The worst situation is where there's a creep effect and this is where your weight continues to increase with higher doses, and you can continue to gain weight the longer you take the medication even if your dose doesn't increase."

"Olanzapine caused a weight gain of eight pounds in six weeks, and it has the creep effect where you can continue to gain weight for as long as you stay on the medication even after you get to your maintenance dose."

"Because not all of these medications work the same for everyone. Sometimes Olanzapine is the only thing that is effective for the person or they started on it before the newer drugs came out, and then sometimes switching to a different antipsychotic just doesn't work."

"Quetiapine is unique in that low doses under 100 milligrams are commonly used to help people with anxiety and sleep."

"These medications can also change your metabolic profile in a dose-dependent manner. That is they can increase your glucose, triglycerides and cholesterol."

"This means you and your doctor can aim to use the least effective dose possible to minimize the negative effects."